Real-World Evidence

Use Of Anti Arrhythmic Drugs Versus Ablation In Atrial Fibrillation (AFib) Report - Clinical And Economic Outcomes

Atrial Fibrillation (AFib) is associated with considerable morbidity and mortality and is characterized by arrhythmia, tachycardia, and/or bradycardia, and symptoms often include heart palpitations, shortness of breath, and weakness.

The objective of this study was to evaluate the economic benefits of anti-arrhythmic drugs (AADs) in comparison to ablation, both as individual treatments and as combination therapy with/ without considering the order of treatment. A Rhythm Control Economic model was used to compare different treatment scenarios assess the economic benefits of AADs (dronedarone, amiodarone, sotalol, flecainide, propafenone, dofetilide, and AADs as a group) vs ablation. The results of the study bring forward interesting insights in comparison of direct and combination therapies.

Contact us at connect@axtria.com with any questions.

Complete the brief form to download the white paper

Recommended insights

Anti Arrhythmic Drugs Vs Ablation in Atrial Fibrillation (AFib) Report

White Paper

The Evolution and Future of Integrated Evidence Planning
Anti Arrhythmic Drugs Vs Ablation in Atrial Fibrillation (AFib) Report

Industry Primer

Real-World Evidence
Anti Arrhythmic Drugs Vs Ablation in Atrial Fibrillation (AFib) Report

Article

Unveiling The Key Trends and Topics: Axtria's Insights from ISPOR US 2024